Changes to the Code
S. 3788 · CLEAR LABELS Act · Reported The text a committee sent back to its chamber, often with changes, recommending a vote.
Reported by committee · step 2 of 5
21 U.S.C. § 333 Penalties
2 changes the bill asks for here, 2 carried out
- Carried out:
Section 303(f) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 333(f)) is amended by adding at the end the following:
(10) (A) Any person who fails to comply with the requirements of section 503(i) shall be subject to a civil monetary penalty in an amount not to exceed 25 percent of the total value of the drug product lot or lots involved. (B) In determining whether to assess a penalty under …
- Carried out:
Section 303(f)(5)(A) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 333(f)(5)(A)) is amended by striking
(1), (2), (3), (4), or (9)
and inserting(1), (2), (3), (4), (9), or (10)
.
§ 333(f)Violations related to devices(4)–(5)
Start of § 333 to (f)(4)(A)(ii) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (4)(B) | (B) | (B) | ||
| In determining the amount of a civil penalty under subparagraph (A)(ii), the Secretary shall take into consideration whether the responsible person is making efforts toward correcting the violation of the requirement of section 355(o), 355(p), or 355–1 of this title for which the responsible person is subject to such civil penalty. | In determining the amount of a civil penalty under subparagraph (A)(ii), the Secretary shall take into consideration whether the responsible person is making efforts toward correcting the violation of the requirement of section 355(o), 355(p), or 355–1 of this title for which the responsible person is subject to such civil penalty. | |||
| (5) | (5) | (5) | ||
| (5)(A) | (A) | (A) | ||
| A civil penalty under paragraph (1), (2), (3), (4), or ( | A civil penalty under paragraph (1), (2), (3), (4), [inserted: (9), ]or ([inserted: 10]) shall be assessed, or a no-tobacco-sale order may be imposed, by the Secretary by an order made on the record after opportunity for a hearing provided in accordance with this subparagraph and section 554 of title 5. Before issuing such an order, the Secretary shall give written notice to the person to be assessed a civil penalty, or upon whom a no-tobacco-sale order is to be imposed, under such order of the Secretary’s proposal to issue such order and provide such person an opportunity for a hearing on the order. In the course of any investigation, the Secretary may issue subpoenas requiring the attendance and testimony of witnesses and the production of evidence that relates to the matter under investigation. | |||
| (5)(B) | (B) | (B) | ||
| In determining the amount of a civil penalty, or the period to be covered by a no-tobacco-sale order, the Secretary shall take into account the nature, circumstances, extent, and gravity of the violation or violations and, with respect to the violator, ability to pay, effect on ability to continue to do business, any history of prior such violations, the degree of culpability, and such other matters as justice may require. A no-tobacco-sale order permanently prohibiting an individual retail outlet from selling tobacco products shall include provisions that allow the outlet, after a specified period of time, to request that the Secretary compromise, modify, or terminate the order. | In determining the amount of a civil penalty, or the period to be covered by a no-tobacco-sale order, the Secretary shall take into account the nature, circumstances, extent, and gravity of the violation or violations and, with respect to the violator, ability to pay, effect on ability to continue to do business, any history of prior such violations, the degree of culpability, and such other matters as justice may require. A no-tobacco-sale order permanently prohibiting an individual retail outlet from selling tobacco products shall include provisions that allow the outlet, after a specified period of time, to request that the Secretary compromise, modify, or terminate the order. | |||
| (5)(C) | (C) | (C) | ||
| The Secretary may compromise, modify, or remit, with or without conditions, any civil penalty which may be assessed under paragraph (1), (2), (3), (4), or (9). The amount of such penalty, when finally determined, or the amount agreed upon in compromise, may be deducted from any sums owing by the United States to the person charged. | The Secretary may compromise, modify, or remit, with or without conditions, any civil penalty which may be assessed under paragraph (1), (2), (3), (4), or (9). The amount of such penalty, when finally determined, or the amount agreed upon in compromise, may be deducted from any sums owing by the United States to the person charged. |
§ 333(f)–(g)
(f)(5)(D)–(9)(B) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (f)(9)(B)(ii)(II) | (II) | (II) | ||
| in the case of a violation that continues after the Secretary provides written notice to such person, $250,000 for the first 30-day period (or any portion thereof) that the person continues to be in violation, and such amount shall double for every 30-day period thereafter that the violation continues, not to exceed $1,000,000 for any 30-day period, and not to exceed $10,000,000 for all such violations adjudicated in a single proceeding. | in the case of a violation that continues after the Secretary provides written notice to such person, $250,000 for the first 30-day period (or any portion thereof) that the person continues to be in violation, and such amount shall double for every 30-day period thereafter that the violation continues, not to exceed $1,000,000 for any 30-day period, and not to exceed $10,000,000 for all such violations adjudicated in a single proceeding. | |||
| (f)(9)(B)(iii) | (iii) | (iii) | ||
| In determining the amount of a civil penalty under clause (i)(II) or (ii)(II), the Secretary shall take into consideration whether the person is making efforts toward correcting the violation of the requirements of the section for which such person is subject to such civil penalty. | In determining the amount of a civil penalty under clause (i)(II) or (ii)(II), the Secretary shall take into consideration whether the person is making efforts toward correcting the violation of the requirements of the section for which such person is subject to such civil penalty. | |||
| (f)(10) | (10) [inserted: ] | |||
| (f)(10)(A) | (A) [inserted: ] | |||
| [inserted: Any person who fails to comply with the requirements of section 503(i) shall be subject to a civil monetary penalty in an amount not to exceed 25 percent of the total value of the drug product lot or lots involved.] | ||||
| (f)(10)(B) | (B) [inserted: ] | |||
| [inserted: In determining whether to assess a penalty under this paragraph against a person, and the amount of such a penalty, the Secretary shall consider—] | ||||
| (f)(10)(B)(i) | (i) [inserted: ] | |||
| [inserted: the size of the business of such person and the gravity of the violation;] | ||||
| (f)(10)(B)(ii) | (ii) [inserted: ] | |||
| [inserted: whether such person received written notice of the noncompliance in advance of such proceeding and was provided an opportunity by the Secretary to correct the violation following such notice; and] | ||||
| (f)(10)(B)(iii) | (iii) [inserted: ] | |||
| [inserted: whether such person acted in good faith to correct the violation following any such notice.] | ||||
| (g) | (g) Violations regarding direct-to-consumer advertising | (g) Violations regarding direct-to-consumer advertising | ||
| (g)(1) | (1) | (1) | ||
| With respect to a person who is a holder of an approved application under section 355 of this title for a drug subject to section 353(b) of this title or under section 262 of title 42, any such person who disseminates or causes another party to disseminate a direct-to-consumer advertisement that is false or misleading shall be liable to the United States for a civil penalty in an amount not to exceed $250,000 for the first such violation in any 3-year period, and not to exceed $500,000 for each subsequent violation in any 3-year period. No other civil monetary penalties in this chapter (including the civil penalty in subsection (f)(4)) shall apply to a violation regarding direct-to-consumer advertising. For purposes of this paragraph: (A) Repeated dissemination of the same or similar advertisement prior to the receipt of the written notice referred to in paragraph (2) for such advertisements shall be considered one violation. (B) On and after the date of the receipt of such a notice, all violations under this paragraph occurring in a single day shall be considered one violation. With respect to advertisements that appear in magazines or other publications that are published less frequently than daily, each issue date (whether weekly or monthly) shall be treated as a single day for the purpose of calculating the number of violations under this paragraph. | With respect to a person who is a holder of an approved application under section 355 of this title for a drug subject to section 353(b) of this title or under section 262 of title 42, any such person who disseminates or causes another party to disseminate a direct-to-consumer advertisement that is false or misleading shall be liable to the United States for a civil penalty in an amount not to exceed $250,000 for the first such violation in any 3-year period, and not to exceed $500,000 for each subsequent violation in any 3-year period. No other civil monetary penalties in this chapter (including the civil penalty in subsection (f)(4)) shall apply to a violation regarding direct-to-consumer advertising. For purposes of this paragraph: (A) Repeated dissemination of the same or similar advertisement prior to the receipt of the written notice referred to in paragraph (2) for such advertisements shall be considered one violation. (B) On and after the date of the receipt of such a notice, all violations under this paragraph occurring in a single day shall be considered one violation. With respect to advertisements that appear in magazines or other publications that are published less frequently than daily, each issue date (whether weekly or monthly) shall be treated as a single day for the purpose of calculating the number of violations under this paragraph. | |||
Rest of § 333 unchanged
21 U.S.C. § 353 Exemptions and consideration for certain drugs, devices, and biological products
The bill's words for this section
- Not carried out:
Section 503 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353) is amended by adding at the end the following —(i) Original Manufacturer and Supply Chain Information.— (1) In general.— No person shall introduce or deliver for introduction into interstate commerce any drug— (A) if it is an active pharmaceutical ingredient, unless the label and certificate of analysis contain the name and place of business of the original manufacturer; or (B) if it is a finished drug product in a package form, unless the label includes, either printed directly or made available through electronic means, the name and place of business of— (i) the original manufacturer of each active pharmaceutical ingredient; (ii) the original manufacturer of the finished drug product; and (iii) the packer or distributor, if any. (2) Multiple original manufacturers.— In the case of a finished drug product for which there are multiple different original manufacturers of an active pharmaceutical ingredient, the requirements of paragraph (1)(B)(i) shall be satisfied if the label includes, either printed directly or made available through electronic means, the name and place of business of each applicable original manufacturer of the active pharmaceutical ingredient for the applicable drug product lot. (3) Effect of noncompliance.— In the case of noncompliance with the requirements of paragraph (1), the Secretary shall have discretion to determine that such noncompliance constitutes misbranding and to assess a civil monetary penalty, as described in section 303(f)(10), except that the Secretary may not treat a violation of this subsection as a criminal violation. (4) Definition of original manufacturer.— For purposes of this subsection, the term
original manufacturer
means the establishment that conducts the majority of the significant phases of manufacturing (chemical, physical, or biological manipulation) to produce the active pharmaceutical ingredient or the finished dosage form..We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: adding at the end the following — QCONTENT.